WO2007122557A2 - Non-invasive glucose sensor - Google Patents
Non-invasive glucose sensor Download PDFInfo
- Publication number
- WO2007122557A2 WO2007122557A2 PCT/IB2007/051395 IB2007051395W WO2007122557A2 WO 2007122557 A2 WO2007122557 A2 WO 2007122557A2 IB 2007051395 W IB2007051395 W IB 2007051395W WO 2007122557 A2 WO2007122557 A2 WO 2007122557A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- level
- blood
- sensing
- extrapolating
- glucose
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 181
- 239000008103 glucose Substances 0.000 title claims abstract description 181
- 239000008280 blood Substances 0.000 claims abstract description 178
- 210000004369 blood Anatomy 0.000 claims abstract description 178
- 230000000694 effects Effects 0.000 claims abstract description 57
- 108010003320 Carboxyhemoglobin Proteins 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 251
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 248
- 238000005259 measurement Methods 0.000 claims description 26
- 238000013213 extrapolation Methods 0.000 claims description 21
- 230000003595 spectral effect Effects 0.000 claims description 3
- 239000012491 analyte Substances 0.000 abstract description 6
- 102000016761 Haem oxygenases Human genes 0.000 description 63
- 108050006318 Haem oxygenases Proteins 0.000 description 63
- 108010054147 Hemoglobins Proteins 0.000 description 15
- 102000001554 Hemoglobins Human genes 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- 210000001525 retina Anatomy 0.000 description 11
- 238000012545 processing Methods 0.000 description 10
- 230000009102 absorption Effects 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 150000003278 haem Chemical class 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 230000006378 damage Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 231100000572 poisoning Toxicity 0.000 description 4
- 230000000607 poisoning effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000012306 spectroscopic technique Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Natural products N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 3
- 238000004847 absorption spectroscopy Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000004867 photoacoustic spectroscopy Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 2
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000000180 cavity ring-down spectroscopy Methods 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012014 optical coherence tomography Methods 0.000 description 2
- 230000005693 optoelectronics Effects 0.000 description 2
- 238000002496 oximetry Methods 0.000 description 2
- 201000011461 pre-eclampsia Diseases 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 238000001055 reflectance spectroscopy Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001745 uvea Anatomy 0.000 description 2
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000004497 NIR spectroscopy Methods 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001517 counterregulatory effect Effects 0.000 description 1
- 108010002255 deoxyhemoglobin Proteins 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 238000004993 emission spectroscopy Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/412—Detecting or monitoring sepsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/083—Measuring rate of metabolism by using breath test, e.g. measuring rate of oxygen consumption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
Definitions
- the present invention relates to an apparatus and method for determining an analyte level in blood, and is more particularly related to an apparatus and method for non-invasively determining the glucose level in blood.
- Diabetes is a disease related to a failure of the biological mechanisms of regulation of the glycemia, i.e. the concentration of glucose in blood.
- the glycemia i.e. the concentration of glucose in blood.
- metabolic affections of the uvea or cataracts - blood glucose level must be monitored as often as possible. This monitoring is essential to help determining when insulin needs to be injected, and in which quantity.
- Non invasive glucose sensors are therefore highly desirable, to increase the frequency of proper monitoring for patients, which won't have to use a finger prick several times a day, this operation being painful and a potential source of infections.
- spectroscopic techniques typically based on the absorption of glucose in the infrared/mid infrared region, using one or more wavelengths to irradiate a sample tissue, usually a body part such as a finger tip or ear lob, where there are enough blood vessels and not too many skin layers.
- the reflected and/or transmitted light intensity is collected and analysed, and the glucose level is calculated, based on the absorbance data and the collected spectra.
- a sensor based on near infrared spectroscopy is described in US patent n°4,655,225, wherein blood glucose determination is performed by analysing infrared light transmitted through a finger.
- the light source has a range from 1000 to 2500 nm, and blood glucose level is determined using two preferred wavelengths.
- the present invention discloses an apparatus for determining heme oxygenase activity and/or a blood glucose level, the apparatus comprising: blood generated CO determination means for determining a blood generated CO level, and first extrapolating means for extrapolating said HO activity and/or said blood glucose level according to said blood generated CO level.
- the invention proposes to determine HO activity and/or the blood glucose level through a blood CO determination. A proper extrapolation may lead to a value of HO activity, and of blood glucose level.
- Carboxyhemoglobin is a stable compound, which results from the interaction of carbon monoxide (CO) with hemoglobin.
- CO carbon monoxide
- the affinity of hemoglobin for carbon monoxide is -240 times higher than that of oxygen, which means that CO competitively binds to the oxygen- carrying hemoglobin, dissociating oxygen and depriving tissues of their oxygen supply.
- CO is a poisonous gas, whose inhalation with strong amounts involves faintnesses, headaches, then asthenia (intense weakness), and finally death by asphyxiation.
- Hb-CO can dissociate in the lungs, releasing the CO molecules into the exhaled breath.
- CO is also endogenously produced in humans.
- the main source of CO is enzymatic heme breakdown into biliverdin, which is induced by the enzyme heme oxygenase- 1 (HO-I).
- HO-I heme oxygenase- 1
- the amount of CO endogenously produced in the body in a given time frame will be referred to as blood generated CO.
- CO in the exhaled breath may include CO that was generated in heme breakdown, as well as CO coming from Hb-CO dissociation in the lungs. Therefore, the amount of CO measured in the breath is linked directly to the blood Hb-CO level, which, in turn, is a measure of the amount of CO which has been absorbed into the blood stream. Because blood CO comprise blood generated CO, and since heme breakdown is induced by the heme oxygenase, the amount of blood CO can be linked to blood Hb-CO and to HO activity.
- heme oxygenase arrow 1 in figure 1
- Hb hemoglobin
- Hb-CO hemoglobin
- the affinity of hemoglobin for CO is -240 times that for oxygen, which makes this process very fast. It is expected that all CO will quickly bind to Hb-CO, after which the CO is slowly released and exhaled when Hb-CO dissociates in the lungs (arrow 3 in figure 1).
- HO presents anti-inflammatory, antiapoptotic, and antiproliferative functions, and its beneficial effects have now been described in diseases as diverse as atherosclerosis and pre-eclampsia: monitoring HO activity is a way to help understanding the mechanisms by which this enzyme gives its protection.
- this combination also leads to an advantageous determination of blood glucose level that permits a continuous monitoring.
- Blood glucose level must be monitored as often as possible, in order to help regulate the glycemia during the day and to reduce the numerous physiological problems that can occur to patients suffering diabetes - among others complicated degenerative affections which, in the eye, are especially retinopathy, metabolic affections of the uvea or cataracts.
- This monitoring is essential to help determining when insulin needs to be injected, and in which quantity.
- HO activity and/or blood glucose level can be extrapolated from blood generated CO level, where the assumption is made that only the CO that has been generated in the body in a given time frame and that has escaped in the lungs can be linked to glucose, while the CO coming from the dissociation of Hb-CO represents the background signal in the measurement.
- Hb-CO has a very slow half-life time, which means that the CO will only slowly be released in the exhaled breath.
- Hb-CO may be representative of the general environment, such as a city or a countryside where the levels of ambient CO, thus of blood CO, are different, as well as an average of any CO changing effects.
- blood generated CO determination means and extrapolating means HO activity and glucose level can be determined.
- said blood generated CO determination means comprise breath CO sensing means, for sensing a breath CO level in breath, Hb-CO sensing means, for sensing a blood carboxyhemoglobin (Hb-CO) level, and blood generated CO level extrapolating means, for extrapolating said blood generated CO level according to said Hb-CO level and said exhaled CO level.
- breath CO sensing means for sensing a breath CO level in breath
- Hb-CO sensing means for sensing a blood carboxyhemoglobin (Hb-CO) level
- blood generated CO level extrapolating means for extrapolating said blood generated CO level according to said Hb-CO level and said exhaled CO level.
- total breath CO comprises said blood generated CO and said CO that was bound to hemoglobin, forming Hb-CO.
- breath CO sensing means a breath CO level in breath can be determined.
- Hb-CO sensing means blood carboxyhemoglobin (Hb-CO) level can be determined. Said blood generated CO can then be extrapolated as a function of Hb-CO level and of breath level.
- said blood generated CO level extrapolating means may further comprise CO computing means for computing a computed CO level according to said blood Hb-CO level.
- CO computing means for computing a computed CO level A relation converting the amount of CO measured in the exhaled breath to the blood Hb-CO level ("Carboxyhemoglobin Levels", http://www.indsci.com/docs/Gas_Carboxy_Intrinsic.pdf) is well known, in particular when studying CO poisoning.
- a CO level can be deducted from a sensed blood Hb-CO level. Said CO level extrapolated from blood Hb-CO will be referred to as computed CO level.
- said breath CO sensing means is adapted to measure both inhaled CO level and exhaled CO level.
- the amount of exhaled CO depends on the amount of Hb-CO, as described before, and on the amount of blood generated CO. Additionally, also the CO that has been inhaled, may at least partially be exhaled again.
- a CO sensing means adapted to measure both inhaled CO level and exhaled CO level all contributions to CO exhaled level can then be taken into account, and the measurement may be more accurate.
- said breath CO sensing means is an optical gas sensor.
- the sensor may use for example direct absorption spectroscopy, photo-acoustic spectroscopy, cavity ringdown spectroscopy, or cavity leak-out spectroscopy
- said blood generated CO level is a function of said exhaled CO level, said inhaled CO level, and said computed CO level.
- the present invention also discloses an apparatus for determining heme oxygenase activity and/or a blood glucose level, the apparatus comprising Hb-CO sensing means for sensing a blood carboxyhemoglobin (Hb-CO) level, and second extrapolating means for extrapolating said HO activity and/or said blood glucose level according to said Hb-CO level.
- Hb-CO sensing means for sensing a blood carboxyhemoglobin (Hb-CO) level
- second extrapolating means for extrapolating said HO activity and/or said blood glucose level according to said Hb-CO level.
- the determination of the blood glucose level and/or HO activity may be performed through an analyte level determination, the analyte being carboxyhemoglobin (Hb-CO).
- Hb-CO carboxyhemoglobin
- blood Hb-CO level can be sensed in a first step, leading to a blood glucose level and/or HO activity determination on the basis of said sensed blood Hb-CO level.
- said second extrapolating means comprises CO level computing means for computing a carbon monoxide level according to said Hb-CO level.
- said second extrapolating means further comprises glucose level computing means for computing said blood glucose level according to said computed CO level.
- CO level can be computed by said CO level computing means, and, in a similar way, glucose level computing means can compute said blood glucose level, using the extrapolation between exhaled CO and blood glucose level.
- an apparatus may comprise CO level calibration means for including an ambient CO level in the computation of said glucose level according to said CO level.
- the ambient CO level may vary, thus influencing the blood CO level.
- the blood CO level may be higher in a city than in the countryside, or may depend on the degree of pollution, and on other external factors. Since the extrapolation of blood glucose level relies on a single extrapolation of a CO level from Hb-CO level, said extrapolated blood glucose level may be shifted, depending on said ambient CO level. Therefore, it would be necessary to take account of an ambient CO level, to ensure that the extrapolation of blood glucose level leads to a correct value.
- said CO level calibration means may comprise CO sensing means for sensing an ambient CO level, and modelling means for modelling Hb-CO level responsive to said ambient CO level.
- modelling means for calculating the changes in Hb-CO levels as a result of changes in ambient CO level, and possibly on other parameters, such as heart rate, respiration rate, and others, the accuracy of the glucose level determination may be improved, or the time between calibrations may be increased.
- said Hb-CO sensing means is non invasive.
- a number of invasive and noninvasive hemoglobin sensors (including hemoglobin compounds such as carboxyhemoglobin, oxyhemoglobin, deoxyhemoglobin) have been developed, in particular to detect CO poisoning.
- non invasive Hb-CO sensing means it becomes possible to provide for a non-invasive blood glucose sensing apparatus, needed to sense blood glucose level a great number of times during the day, without having to endure the inconveniences of an invasive glucose detector.
- An apparatus according to the invention may further comprise calibration means for calibrating said HO activity and/or said blood glucose level obtained by extrapolation.
- an apparatus preferably comprises glucose level calibration means, in order to calibrate the relation between Hb-CO and glucose, and HO activity.
- Said calibration means may comprise at least one of reference glucose sensing means for sensing a reference glucose level, and/or comparison means for comparing values of said blood glucose level and/or said HO activity obtained at different measurement times
- Calibrations of different kinds are contemplated.
- One option would be to sense a reference glucose level using reference glucose sensing means.
- the calibration means may be adapted to sense a reference glucose level and to adjust said extrapolated glucose level to said reference glucose level.
- the calibration means may comprise either one or both of the aforementioned calibration options.
- Said glucose level calibration means can be adapted to sense a reference glucose level and to adjust said extrapolated glucose level to said reference glucose level, on a regular time basis, possibly on a daily basis.
- blood glucose level is determined directly according to a sensed blood Hb-CO
- different parameters may influence the measurement, as blood Hb-CO level may be influenced by a great number of parameters and physiologic functions.
- These other physiologic functions affecting blood Hb-CO level typically give a slow change of Hb- CO level over time. Therefore, after a certain amount of time, it is contemplated to recalibrate the glucose measurement. This calibration would preferably be made on a regular time basis, for example once a day.
- blood glucose level is determined according to blood generated CO level
- a calibration may also be necessary, since the assumption is made that always the same fraction of generated CO will escape directly through the lungs. It could be that this fraction vary, depending for instance on the general environment, where the ambient CO influences the level of blood Hb-CO, and then the level of haemoglobin. It is also to be noted that in this case however, blood Hb-CO is considered as a background measure for blood CO.
- said reference glucose sensing means is a fingerstick type glucose sensor, showing the well-defined accuracy and performances needed for reference.
- said comparison means is adapted to make at least one of the following comparisons: values of said HO activity, ratios of said blood generated CO to said breath CO, ratios of said blood generated CO to said computed CO, said values and ratios being obtained at different measurement times.
- comparison means may be useful, as a tool to monitor the evolution of different parameters over time, with a reference measurement, that could be made with another sensor or with the same sensor at different times.
- Said Hb-CO sensing means can be adapted to provide a sensing accuracy of at least 0,5 % Hb-CO.
- a change of 1.6 mmol/L blood glucose level corresponds to a change of 3.3 ppm exhaled CO, which in turn corresponds with around 0.53% Hb-CO. Therefore a non-invasive Hb-CO detector would need to have accuracy better than roughly 0.5%.
- Preferred glucose accuracy would be of 1 mmol/L, which corresponds to an Hb-CO accuracy of 0.3 %. It is to be noted that an exact absolute value of blood Hb-CO level need not be measured, because the blood glucose determination is calibrated, but instead the repeatability of the measurement is of great importance.
- said Hb-CO sensing means may comprise: illuminating means for illuminating a sample tissue with a plurality of wavelengths, collecting means for collecting transmitted and/or reflected light, and Hb-CO computing means for computing the Hb-CO level responsive to transmitted, emitted and/or reflected light intensity.
- Oximetry is a technique used to measure hemoglobin level, which measures the increased absorbance present during a pulsatile flow when the arterial bed expands from the increased systolic volume.
- an oximeter measures the transmission of light at different wavelengths through a sample tissue. Since the different hemoglobin compounds (oxygenated hemoglobin, reduced hemoglobin and carboxyhemoglobin) don't have the same absorption spectra, their concentrations can be determined from the relative absorptions at different wavelengths.
- said Hb-CO sensing means may comprise illuminating means for illuminating a sample tissue with a plurality of wavelengths, collecting means for collecting transmitted and/or reflected light, spectroscopic means for separating transmitted and/or reflected light depending on spectral bands from said plurality of wavelengths, and Hb-CO computing means for computing said Hb-CO level according to separated transmitted/reflected light intensity.
- spectroscopic and interferometric techniques are contemplated, wherein Hb-CO level can be determined from the intensity of the signal light.
- the sensing techniques may include Raman spectroscopy, photo-acoustic spectroscopy, direct absorption spectroscopy, fluorescence spectroscopy, optical coherence tomography, thermal emission spectroscopy and diffuse reflection spectroscopy.
- interferometry like in optical coherence tomography, the light source is split into at least two beams, a reference beam and a probe beam, the probe beam is usually reflected on the sample tissue. After having traveled over different paths, the probe and reference beams are recombined, and interferences can be obtained, with characteristics depending on the sample tissue properties and composition.
- a preferred apparatus may use a Michelson or a Mach-Zender interferometer, to measure reflection of light from the tissue.
- Said plurality of wavelengths is in the range of about 450 nm to about 1900 nm, where carboxyhemoglobin has the strongest absorption.
- Said plurality of wavelengths may comprise any number of wavelengths, preferably at least three or more for improved reliability and accuracy.
- Said illuminating means may comprise light sources, among others light emitting diodes, lasers, halogen sources or any other light sources. Sources of different widths and coherence are contemplated, in particular white light sources, broadband or monochromatic sources. In the latter case, multiplexing means can also be associated, to provide a single illuminating beam on the tissue. Moreover, said illuminating means may further comprise imaging optics, including one or more lenses, light guiding means, reflectors or focusing means, for focusing the light, and direct it into the sample tissue.
- Suitable collecting means and spectroscopic means may comprise detectors with a detection window in the range of said plurality of wavelengths, like photodiodes or avalanches photodiodes, integrating spheres, photometers, or any suitable optoelectronics component, wavelength selecting devices, optical spectrum analyzer, spectrometer, whose resolution may be of a few nm over the entire range defined by said plurality of wavelengths.
- detectors have a uniform sensitivity over the range of wavelengths.
- said collecting means may also include demultiplexing means, for demultiplexing the light at different wavelengths, amplifying means for amplifying the sensed signal, filtering means, with uniform or well-defined response over the wavelengths range.
- Computing means comprises filtering, signal processing tools and techniques well-known in the art.
- the sample tissue is a blood profused tissue, such as a finger or an ear lobe.
- a retina glucose sensor according to the invention may use reflection spectroscopic techniques.
- the transparency of the eye must be taken into account.
- the invention also proposes a method for determining heme oxygenase activity and/or a blood glucose level, comprising the steps of determining a blood generated CO level, and extrapolating said heme oxygenase activity and/or said glucose level according to said blood generated CO level.
- the step of extrapolating said HO activity and/or said glucose level comprises the steps of sensing a breath CO level in breath, sensing a blood carboxyhemoglobin (Hb-CO) level, and extrapolating said HO activity and/or said blood generated CO according to said Hb-CO level and said breath CO level.
- Hb-CO blood carboxyhemoglobin
- the step of sensing a breath CO level comprises sensing an exhaled CO level and an inhaled CO level
- the step of extrapolating said blood generated CO level comprises the step of computing a carbon monoxide (CO) level according to said Hb-CO level, and wherein said blood generated CO is a function of said computed CO level, said exhaled CO level, said inhaled CO level.
- CO carbon monoxide
- the invention also provides for a method for non invasively determining HO activity and/or a blood glucose level, comprising the steps of sensing a blood carboxyhemoglobin (Hb-CO) level, and extrapolating said HO activity and/or said glucose level according to said Hb-CO level.
- a blood carboxyhemoglobin (Hb-CO) level sensing a blood carboxyhemoglobin (Hb-CO) level, and extrapolating said HO activity and/or said glucose level according to said Hb-CO level.
- the step of extrapolating said HO activity and/or said glucose level comprises the steps of: computing a carbon monoxide (CO) level according to said Hb-CO level, and computing said glucose level according to said computed CO level.
- CO carbon monoxide
- a method according to the present invention may further comprise the step of calibrating said glucose level and/or said HO activity obtained by extrapolation.
- the step of sensing blood Hb-CO may be non invasive.
- the invention provides a method for non invasively determining heme oxygenase activity and/or blood glucose level according to anyone of claims 22-24, 27-28 using an apparatus according to anyone of claims 1-6, 12-21, and/or according to anyone of claims 25- 28 using an apparatus according to anyone of claims 7-21.
- figure 1 is a diagram explaining the relation between heme oxygenase and carbon monoxide, useful for the present invention
- figure 2 is a functional diagram of an apparatus for determining HO activity and/or blood glucose level, according to a first preferred embodiment of the present invention
- figure 3 is a functional diagram of an apparatus for determining HO activity and/or blood glucose level
- figure 4 is a schematic view of a carboxyhemoglobin sensor suitable for use in an apparatus for determining HO activity and/or blood glucose level
- figure 5 is a view of another carboxyhemoglobin sensor in an apparatus for determining HO activity and/or blood glucose level, in an alternative embodiment of the present invention.
- Figure 2 is a functional diagram of an apparatus for determining HO activity and/or blood glucose level, according to a first preferred embodiment of the present invention.
- the apparatus comprises blood generated CO determination means, whereby a blood generated CO is determined, said blood generated CO being defined as the amount of CO produced in a given timeframe (for example by heme breakdown in the patient's body), and extrapolating means 80 for extrapolating HO activity and/or blood glucose level according to said blood generated CO.
- Said blood generated CO determination means comprise breath CO sensing means 50, Hb- CO sensing means 10, blood generated CO extrapolating means 60.
- Breath CO sensing means 50 may be adapted for measuring both inhaled and exhaled breath of the patient.
- breath CO sensing means 50 are provided with a gas tube 52 through which at least some of the breath of the patient is flown.
- the gas travels away from the breath CO sensing means 50, and when the patient exhales, the gas travels towards the breath CO sensing means 50. In this way, the CO concentration in the inhaled and exhaled breath can be measured.
- Breatg CO sensing means 50 may be an optical gas sensor, using for example direct absorption spectroscopy, photo-acoustic spectroscopy, cavity ringdown spectroscopy, or cavity leak-out spectroscopy (CALOS).
- direct absorption spectroscopy photo-acoustic spectroscopy
- cavity ringdown spectroscopy cavity leak-out spectroscopy
- the apparatus further comprises a Hb-CO sensing means 10, which are adapted to measure a blood Hb-CO level, and are preferably a non-invasive sensor, using absorption and/or spectroscopic techniques.
- Hb-CO sensing means will be described in more details with reference to figures 4 and 5.
- the data from breath CO sensing means 50 and Hb-CO sensing means 10 are processed by blood generated CO extrapolating means 60.
- CO computing means 62 calculates a CO level according to said Hb-CO level, using the well-known extrapolation between CO and Hb-CO levels. Then, said blood generated CO level is determined using the values of inhaled CO level, exhaled CO level and computed CO level.
- both HO activity and blood glucose level may be calculated.
- said blood generated CO determination means, CO computing means 62, and extrapolating means 60, 80 are also provided with all necessary electronics, signal processing and computing tools.
- the HO activity and/or glucose sensing may be performed without harm and as often as necessary, since Hb-CO sensing means 10 are non-invasive.
- Said extrapolating means 80 preferably comprise display and memory for storing said glucose level data and HO activity data. This feature may be useful for monitoring disease, e.g. to see if the condition of the patient improves or get worse.
- the apparatus further comprises calibration means 31.
- Said calibration means 31 include reference glucose sensing means 35, such as a fingerstick sensor, which is a reliable and accurate glucose sensor. Blood glucose level is measured with the fingerstick sensor 35 on a regular time basis, in particular once a day, as a reference glucose level. This reference glucose level is in turn compared to said extrapolated glucose value.
- said calibrations means 31 are provided with electronics, soft and signal processing tools, so as to perform the aforementioned comparison, and to adjust and assign in the extrapolation said extrapolated glucose level to said reference glucose level. This operation may be done once a day, and said calibration means 31 may also include features such as an alarm together with a LED, flashing to warn the user when a calibration is required.
- said calibration means 31 may also be provided with comparison means 32, in order to make comparisons between different parameters values obtained at different times, as a tool to monitor the evolution of different parameters over time, with a reference measurement, that could be made with another sensor or with the same sensor at different times.
- said comparison means are adapted to make at least one of the following comparisons: values of said HO activity, ratios of said blood generated CO to said breath CO, ratios of said blood generated CO to said computed CO, said values and ratios being obtained at different measurement times.
- a possible ratio is the ratio between blood generated CO and breath CO or computed CO, because this value gives the ratio between the currently generated CO and the CO generated in a longer time period.
- this ratio can be indicative of the change in CO production and thus the change of HO activity.
- the apparatus of figure 2 may be used as follows.
- a first glucose calibration is performed, consisting in measuring a reference glucose level with said fingerstick sensor, and in determining a first extrapolated glucose level value and/or HO activity value based on blood generated CO measurement. These two values are compared and said extrapolated glucose value is adjusted to said reference value. Later on, when the user needs to perform a new glucose level determination, the user need not perform the glucose level calibration.
- every following HO activity and/or glucose determination consists in blood generated CO level determination, based on the sensed values of blood Hb-CO level, exhaled CO and inhaled CO levels, followed by an extrapolation to determine glucose level value and/or HO activity, with all necessary computing steps, and optionally calibration as well.
- FIG 3 is a functional diagram of an apparatus for determining HO activity and/or blood glucose level, according to a second preferred embodiment of the present invention.
- the apparatus comprises non- invasive Hb-CO sensing means 10, glucose extrapolating means 20, and glucose level calibration means 30.
- Hb-CO sensing means 10 are adapted to measure a blood Hb-CO level, and are preferably a non-invasive sensor, using absorption and/or spectroscopic techniques. Preferred embodiments of Hb-CO sensing means will be described in more details with reference to figures 4 and 5.
- Glucose level extrapolating means 20 comprises CO level computing means 25 and glucose level computing means 28.
- Electronics, signal processing and computing tools are provided with CO level computing means 25, which are adapted to compute a value of CO level according to said Hb-CO level, using the well-known relation between blood Hb-CO and exhaled CO.
- said glucose level computing means 28 are also provided with all necessary electronics, signal processing and computing tools, to compute said glucose level, using the aforementioned relation between exhaled CO and blood glucose level.
- the glucose sensing may be performed without harm and as often as necessary, since Hb-CO sensing means are non- invasive.
- Said glucose level extrapolating means 20 preferably comprise display and memory for storing said glucose level data. This feature may be useful for monitoring blood glucose value in time.
- the apparatus further comprises glucose level calibration means 30, a calibration being required because Hb-CO level is also influenced by other physiological factors, such as asthma for example, which give typically a slow change of Hb-CO level over time.
- Said glucose level calibration means 30 include reference glucose sensing means 35, such as a fingerstick sensor, which is a reliable and accurate glucose sensor, and adjusting means 38. Blood glucose level is measured with the fingerstick sensor 35 on a regular time basis, in particular once a day, as a reference glucose level. This reference glucose level is in turn compared to said extrapolated glucose value obtained through a Hb-CO measurement followed by an extrapolation.
- said adjusting means 38 are provided with electronics, soft and signal processing tools, so as to perform the aforementioned comparison, and to adjust and assign in the extrapolation said extrapolated glucose level to said reference glucose level.
- This operation may be done once a day, and said adjusting means 38 may also include features such as an alarm together with a LED, flashing to warn the user when a calibration is required. It is also contemplated that no Hb-CO sensing is possible as long as the calibration has not been made.
- the apparatus may also be provided with CO level calibration means 40 for including a ambient CO level in the computation of said glucose level according to said CO level.
- Said CO level calibration means 40 is comprised of CO sensing means 45, such as a gas detector commonly known in the art, together with modelling means 48 for modelling Hb-CO level responsive to said ambient CO level.
- Modelling means may include a model to evaluate the changes in Hb-CO levels as a result of changes in ambient CO level. Possibly other parameters, such as heart rate, respiration rate, and others, may also be taken into account. Once again, all necessary electronics and signal processing tools are provided with said modelling means 48.
- the apparatus of figure 3 may be used as follows.
- a first glucose calibration is performed, consisting in measuring a reference glucose level with said fingerstick sensor, and in determining a first extrapolated glucose level value based on Hb-CO level measurement. These two values are compared and said extrapolated glucose value is adjusted to said reference value.
- the user need not perform the glucose level calibration, for a given time period, for example a day.
- Another calibration may also include a ambient CO level, measured through a simple gas detector, and being included in a model for determining the variations of Hb-CO level responsive to ambient CO variations. This calibration may be included at each glucose level determination.
- every following glucose determination consists in blood Hb-CO level determination followed by an extrapolation to determine glucose level value, with all necessary computing steps, and optionnaly the CO calibration as well.
- the user may be warned to perform a new glucose calibration.
- Hb-CO sensing means 10 for measuring blood Hb-CO and hence blood glucose level in a tissue sample is depicted figure 4, said Hb-CO sensing means relying on the same principles as pulse oximetry, with additional wavelengths.
- Hb-CO sensing means 10 comprise a light source 101, which is directed towards the tissue bed, for example an ear lob 104.
- the light source 101 may be a broadband light source, in the range of 400-1900 nm, where carboxyhemoglobin has strong absorption properties, the light source being preferably uniform over the given range.
- one or more monochromatic sources are used, such as laser diodes, preferably of the same width, with their driving electronics. Different measurements can be performed and added. Another option is to use different monochromatic sources along with a multiplexer and to perform a single measurement.
- the light beam from the light source passes through imaging optics 103, comprising one or more lenses for focusing the light.
- imaging optics 103 comprising one or more lenses for focusing the light.
- the light beam is then focused onto the ear lob 104.
- the absorbance is given by the Beer-Lambert law, wherein the absorbance at a given wavelength is given by :
- AX 11 E 1 C 1 X L I 1 where C 1 is the absorptivity of a component i at wavelength ⁇ , C 1 is the concentration of component i, and 1 is the light path-length.
- the increased absorbance present during a pulsatile flow when the arterial bed expands from the increased systolic volume is a measure of the hemoglobin components absorption, in particular blood Hb-CO level may be obtained from the absorbance data.
- Preferred wavelengths correspond to peak absorption of different hemoglobin components, for example, 530,6 nm und 583 nm.
- the overall accuracy may be improved by using several wavelengths. However, it is to be noted that the wavelengths don't have to be at the peaks, as contrast, i.e the difference between the signals when the CO level shifts, is the most important parameter.
- the wavelengths may be 630 nm, 720 nm and 900 nm, in an exemplary embodiment when only three wavelengths are used.
- the transmitted light is directed towards a detector 106.
- the detector 106 preferably has a uniform sensitivity in the range of wavelengths used for sensing Hb-CO, i.e., 400-1900 nm.
- Hb-CO level is determined from the detected signal, using computing means 1008 with filtering and signal processing tools well-known in the art.
- Alternative Hb-CO sensing means for measuring blood Hb-CO and hence blood glucose level in a sample tissue is depicted figure 5, said Hb-CO sensing means relying on reflection spectroscopy.
- a preferred region of interest is the retina, because measuring Hb-CO level in the retina may give an indication of the risk of retina damage due to diabetes, or may be used to screen for diabetes.
- Hb-CO sensing means 10 comprise a light source 201, which is directed towards the eye 204.
- the light source 101 may be a broadband light source, at least in the range of 400-900 nm, preferably uniform in the given range.
- the light beam from the light source passes through imaging optics 203, comprising one or more lenses for focusing the light.
- the light beam is then directed into the eye 204 and focused onto the retina 205.
- imaging optics 203 comprising one or more lenses for focusing the light.
- the light beam is then directed into the eye 204 and focused onto the retina 205.
- it is important that the intensity of the light source 201 is low enough to make sure that no damage to the retina 205 is caused.
- the light reflected off the retina is redirected towards the light source 201.
- a beam splitter 202 sends the reflected light towards a detector 206.
- the detector 206 preferably has a uniform sensitivity in the range of wavelengths used for sensing Hb-CO in the retina, i.e., 400-900 nm, and includes a spectrometer for measuring the absorption spectrum of the reflected light, or an optical wavelength analyzer.
- an optoelectronic or electrical amplifier may be added, in order to amplify the detected signal.
- Hb-CO level is then determined, through the use of computing means 208, including filters and signal processing tools.
- the light sources 101, 201 may be broadband light sources or rely on a set of monochromatic sources, such as laser diodes, preferably of the same width, with their driving electronics. Different measurements can be performed and added. Another option is to use different monochromatic sources along with a multiplexer and to perform a single measurement, as it is the case for broadband light source. Tunable sources may further be employed. When broadband light source are contemplated, spectrometer means may be used in order to measure the intensity of light at several wavelengths.
- an apparatus and a method for determining HO activity is disclosed, and linked to a blood glucose level, based on the determination of a blood analyte level along with extrapolating means to get the actual HO activity as well as the actual blood glucose level, wherein calibration means are also preferably involved.
- this apparatus may be implemented in a non-invasive way, with improved accuracy and repeatability.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Emergency Medicine (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Obesity (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009506025A JP2009535072A (en) | 2006-04-21 | 2007-04-18 | Non-invasive glucose sensor |
US12/297,235 US20090270700A1 (en) | 2006-04-21 | 2007-04-18 | Non-invasive glucose sensor |
EP07735534A EP2012657A2 (en) | 2006-04-21 | 2007-04-18 | Non-invasive glucose sensor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06300390 | 2006-04-21 | ||
EP06300390.9 | 2006-04-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007122557A2 true WO2007122557A2 (en) | 2007-11-01 |
WO2007122557A3 WO2007122557A3 (en) | 2009-06-18 |
Family
ID=38625393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2007/051395 WO2007122557A2 (en) | 2006-04-21 | 2007-04-18 | Non-invasive glucose sensor |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090270700A1 (en) |
EP (1) | EP2012657A2 (en) |
JP (1) | JP2009535072A (en) |
CN (1) | CN101553160A (en) |
WO (1) | WO2007122557A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7809418B2 (en) | 2007-10-04 | 2010-10-05 | The Curators Of The University Of Missouri | Optical device components |
US20110071598A1 (en) * | 2009-09-24 | 2011-03-24 | Nellcor Puritan Bennett Llc | Photoacoustic Spectroscopy Method And System To Discern Sepsis From Shock |
US7961305B2 (en) | 2007-10-23 | 2011-06-14 | The Curators Of The University Of Missouri | Optical device components |
US7961304B2 (en) | 2007-09-13 | 2011-06-14 | The Curators Of The University Of Missouri | Optical device components |
US8340738B2 (en) | 2008-05-22 | 2012-12-25 | The Curators Of The University Of Missouri | Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis |
US8552359B2 (en) | 2009-04-01 | 2013-10-08 | The Curators of the Univesity of Missouri | Optical spectroscopy device for non-invasive blood glucose detection and associated method of use |
US10542919B2 (en) | 2008-03-25 | 2020-01-28 | St. Louis Medical Devices, Inc. | Method and system for non-invasive blood glucose detection utilizing spectral data of one or more components other than glucose |
US11122996B2 (en) | 2016-10-03 | 2021-09-21 | Hamamatsu Photonics K.K. | Blood glucose measurement device, blood glucose calculation method, and blood glucose calculation program |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8868149B2 (en) * | 2009-07-30 | 2014-10-21 | Oxitone Medical Ltd. | Photoplethysmography device and method |
US20170196481A1 (en) * | 2014-06-25 | 2017-07-13 | Purdue Research Foundation | Systems and methods for determining a concentrationof glucose in exhaled breadth |
KR102290277B1 (en) | 2014-08-27 | 2021-08-17 | 삼성전자주식회사 | Method and apparatus for processing biosignal |
US9459201B2 (en) | 2014-09-29 | 2016-10-04 | Zyomed Corp. | Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing |
KR102335739B1 (en) | 2014-12-19 | 2021-12-06 | 삼성전자주식회사 | Apparatus and method for measuring a blood glucose in a noninvasive manner |
EP3302229B1 (en) * | 2015-05-29 | 2024-09-04 | Koninklijke Philips N.V. | System for increasing a patient's compliance with a therapy relating to an upper airway disorder |
US9554738B1 (en) | 2016-03-30 | 2017-01-31 | Zyomed Corp. | Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing |
KR101746352B1 (en) | 2016-04-29 | 2017-06-12 | 다담마이크로 주식회사 | Non-invasive blood glucose measuring device and method using OTDR and OFDR |
FI127811B (en) * | 2016-11-21 | 2019-03-15 | Helsingin Yliopisto | Device for sampling one or more analytes |
US12089930B2 (en) | 2018-03-05 | 2024-09-17 | Marquette University | Method and apparatus for non-invasive hemoglobin level prediction |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6397093B1 (en) * | 1996-12-05 | 2002-05-28 | Essential Medical Devices, Inc. | Non-invasive carboxyhemoglobin analyzer |
US6415236B2 (en) * | 1999-11-30 | 2002-07-02 | Nihon Kohden Corporation | Apparatus for determining concentrations of hemoglobins |
-
2007
- 2007-04-18 WO PCT/IB2007/051395 patent/WO2007122557A2/en active Application Filing
- 2007-04-18 CN CNA2007800141370A patent/CN101553160A/en active Pending
- 2007-04-18 US US12/297,235 patent/US20090270700A1/en not_active Abandoned
- 2007-04-18 EP EP07735534A patent/EP2012657A2/en not_active Withdrawn
- 2007-04-18 JP JP2009506025A patent/JP2009535072A/en active Pending
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7961304B2 (en) | 2007-09-13 | 2011-06-14 | The Curators Of The University Of Missouri | Optical device components |
US7809418B2 (en) | 2007-10-04 | 2010-10-05 | The Curators Of The University Of Missouri | Optical device components |
US7961305B2 (en) | 2007-10-23 | 2011-06-14 | The Curators Of The University Of Missouri | Optical device components |
US10542919B2 (en) | 2008-03-25 | 2020-01-28 | St. Louis Medical Devices, Inc. | Method and system for non-invasive blood glucose detection utilizing spectral data of one or more components other than glucose |
US11147482B2 (en) | 2008-03-25 | 2021-10-19 | St. Louis Medical Devices, Inc. | Method and system for non-invasive blood glucose measurement using signal change of the non-glucose components induced by the presence of glucose |
US11076781B2 (en) | 2008-05-22 | 2021-08-03 | St. Louis Medical Devices, Inc. | Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis |
US10080515B2 (en) | 2008-05-22 | 2018-09-25 | St. Louis Medical Devices, Inc. | Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis |
US9566024B2 (en) | 2008-05-22 | 2017-02-14 | St. Louis Medical Devices, Inc. | Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis |
US9579049B2 (en) | 2008-05-22 | 2017-02-28 | St. Louis Medical Devices, Inc. | Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis |
US9629576B2 (en) | 2008-05-22 | 2017-04-25 | St. Louis Medical Devices, Inc. | Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis |
US9788764B2 (en) | 2008-05-22 | 2017-10-17 | St. Louis Medical Devices, Inc. | Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis |
US9814415B2 (en) | 2008-05-22 | 2017-11-14 | St. Louis Medical Devices, Inc. | Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis |
US9877670B2 (en) | 2008-05-22 | 2018-01-30 | St. Louis Medical Devices, Inc. | Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis |
US10070809B2 (en) | 2008-05-22 | 2018-09-11 | St. Louis Medical Devices, Inc. | Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis |
US12036019B2 (en) | 2008-05-22 | 2024-07-16 | St. Louis Medical Devices, Inc. | Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis |
US11986291B2 (en) | 2008-05-22 | 2024-05-21 | St. Louis Medical Devices, Inc. | Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis |
US10959650B2 (en) | 2008-05-22 | 2021-03-30 | St. Louis Medical Devices, Inc. | Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis |
US10973442B2 (en) | 2008-05-22 | 2021-04-13 | St. Louis Medical Devices, Inc. | Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis |
US8340738B2 (en) | 2008-05-22 | 2012-12-25 | The Curators Of The University Of Missouri | Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis |
US11553859B2 (en) | 2008-05-22 | 2023-01-17 | St. Louis Medical Devices, Inc. | Method and system for non-invasive optical blood glucose detection utilizing spectral data analysis |
US8552359B2 (en) | 2009-04-01 | 2013-10-08 | The Curators of the Univesity of Missouri | Optical spectroscopy device for non-invasive blood glucose detection and associated method of use |
US20110071598A1 (en) * | 2009-09-24 | 2011-03-24 | Nellcor Puritan Bennett Llc | Photoacoustic Spectroscopy Method And System To Discern Sepsis From Shock |
US8798704B2 (en) * | 2009-09-24 | 2014-08-05 | Covidien Lp | Photoacoustic spectroscopy method and system to discern sepsis from shock |
US11122996B2 (en) | 2016-10-03 | 2021-09-21 | Hamamatsu Photonics K.K. | Blood glucose measurement device, blood glucose calculation method, and blood glucose calculation program |
Also Published As
Publication number | Publication date |
---|---|
WO2007122557A3 (en) | 2009-06-18 |
JP2009535072A (en) | 2009-10-01 |
US20090270700A1 (en) | 2009-10-29 |
CN101553160A (en) | 2009-10-07 |
EP2012657A2 (en) | 2009-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090270700A1 (en) | Non-invasive glucose sensor | |
JP5175179B2 (en) | Improved blood oxygenation monitoring method by spectrophotometry | |
US6456862B2 (en) | Method for non-invasive spectrophotometric blood oxygenation monitoring | |
US7072701B2 (en) | Method for spectrophotometric blood oxygenation monitoring | |
US5983122A (en) | Apparatus and method for improved photoplethysmographic monitoring of multiple hemoglobin species using emitters having optimized center wavelengths | |
US6842635B1 (en) | Optical device | |
US8406839B2 (en) | Method and apparatus for determining blood analytes | |
JP2007509718A5 (en) | ||
JP4361822B2 (en) | Method and apparatus for measuring component concentration of target object | |
JPH0295262A (en) | Method and instrument for measuring hemoglobin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780014137.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007735534 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07735534 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12297235 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009506025 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |